abc27

ImmuneWalk Therapeutics Announces Positive Results from Phase 1 SAD/MAD Study of IW-601, a First-In-Class Therapeutic with Broad Potential in Inflammatory and Autoimmune Diseases

Phase 1 Clinical Trial Met All Primary and Secondary Endpoints and Demonstrated Positive Safety, Pharmacokinetics, and Mechanistic Validation Clinical Data Build Upon Robust Preclinical Activity Seen ...
Nasdaq

Corbus Pharmaceuticals Reports No Neuropsychiatric Events in Phase 1 SAD Study of CRB-913, Advancing to MAD Portion

Corbus Pharmaceuticals reports no neuropsychiatric events in CRB-913 trial, advancing to multiple ascending dose phase. Study completion projected for Q3 2025. Corbus Pharmaceuticals Holdings Inc. has ...
Seeking Alpha

Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis

Carlsbad, CA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc (PALI), (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel ...
Insider Monkey

Neumora Therapeutics Initiates Phase 1 Study for Schizophrenia Drug NMRA-861

Neumora Therapeutics Inc. (NASDAQ:NMRA) is one of the best IPO stocks to buy according to Wall Street analysts. Earlier on July 9, Neumora Therapeutics initiated a Phase 1 single-ascending ...
Morningstar

MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

This milestone follows the completion of dosing in the single ascending dose (SAD) portion of the study. According to data reviewed to date, no serious or dose-limiting adverse events have been ...
Nasdaq

Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging ...

NORWOOD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the completion of the ...